

Date: 28th July, 2025

To,
BSE Limited
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

Ref.: BSE Scrip Code No. “533138”

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai – 400 051

Ref.: “ASTEC”

Debt Segment NSE:
NCD-ASTEC-ISIN: INE563J08023

Sub.: Press Release

The Board of Directors of Astec LifeSciences Limited (“the Company”), at its Meeting held on Wednesday, 28th July, 2025, has approved the Unaudited Financial Results (both Standalone and Consolidated) for the Quarter ended 30th June, 2025.

We enclose a copy of the Press Release and the same is being placed on the website of the Company.

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)

Encl.: As Above

ASTEC LIFESCIENCES LIMITED

“Godrej One”, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (E), Mumbai-400079, India

CIN: L99999MH1994PLC076236

PRESS RELEASE

Mumbai, 28th July, 2025: Astec LifeSciences Limited (“Astec”) has today announced its financial results for the first quarter ended June 30, 2025

FINANCIAL OVERVIEW

Q1 FY26 Financial Summary

- The Company reported consolidated total income of Rs. 91.6 crore in Q1FY26 as compared to Rs. 70.3 crore in Q1FY25. The consolidated total income in Q1FY 26 increased by 30.3% over Q1 FY25.
- The Company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1FY26 as compared to loss of Rs. 45.3 crore in the same period last year.

HIGHLIGHTS OF CONSOLIDATED FINANCIAL PERFORMANCE (Q1FY26)

(in Rs. crore)

Particulars	Q1FY26	Q1FY25	% Increase
Total Income	91.6	70.3	30.3%
Earnings before depreciation, interest and taxes (EBITDA)	(10.5)	(45.3)	NM
Profit Before Tax (PBT)	(33.0)	(61.6)	NM
Net Profit after Tax (PAT)	(33.0)	(39.7)	NM

NM: Not Measurable

CHAIRMAN’S COMMENTS

Commenting on the performance, Mr. N B Godrej, Chairman, Astec LifeSciences Limited, said:

Astec reported improvement in performance on a year on year basis on the back of improvement in volumes & contribution in its enterprise business. Revenue in enterprise & CDMO businesses increased year on year by 68.2% & 85.7% respectively. This also resulted in reduction of EBITDA losses as compared to Q1 FY25, which also had an impact of write down of Inventories of INR 18.5 crore.

Revenue from Operations (in Rs. crore)	Q1FY26	Q1FY25	% Increase
Category Breakdown			
Enterprise	36.5	21.7	68.2%
Contract Manufacturing & New Products	54.6	29.4	85.7%
Other Trading Sales	0.0	18.3	NM
Geography Breakdown			
Exports	45.9	31.0	48.1%
Domestic	45.2	38.4	17.7%

- ENDS -

About Astec LifeSciences Limited

Astec LifeSciences Limited (Astec) was incorporated in 1994 and is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. Astec has a healthy sales mix of both exports and domestic sales. Our exports are to over 17 countries including the United States and countries across Europe, West Asia, South-East Asia and Latin America and Africa.

For more information on the Company, please log on to www.godrejastec.com

For further information, please contact:

S. Varadaraj
Godrej Agrovvet Limited
Email: s.varadaraj@godrejagrovvet.com
Tel No.: +91 22 2519 4864

Mugdha Khare
Astec LifeSciences Limited
Email: mugdha.khare@godrejastec.com
Tel No.: +91 22 2519 5777

Amit Pendse
Godrej Agrovvet Limited
Email: amit.pendse@godrejagrovvet.com
Tel No.: +91 22 2519 4488

Disclaimer: "Some of the statements in this communication may be 'forward looking statements' within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Company's operations include changes in industry structure, significant changes in political and economic environment in India and overseas, tax laws, import duties, litigation and labour relations."